Innovation Pharmaceuticals Inc (IPIX)

[djs7]

Brilacidin Activ trial, somewhat hopeful.

Hey, this one failed primary endpoint on Phase 2B data, but still going to an advanced stage 3 as part of govt Activ trial.

Shionogi’s NIH-backed COVID-19 treatment is advancing to late-stage testing after the FDA finalized the drug’s study design. The trial is part of the National Institutes of Health’s ACTIV-2 study, which has been exploring multiple potential COVID outpatient therapies since late 2020. So far, data on Shionogi’s treatment has been mixed : Interim phase 2a results found that the therapy, dubbed S-217622, significantly reduced viral load, but phase 2b data found no major change in clinical symptoms, chalking up a failure on the primary endpoint . Story

https://www.fiercepharma.com/pharma/covid-tracker-pfizer-biontech-moderna-vaccine-johnson-johnson-fda-booster-shot-antiviral

Keep in mind this Shionogi was for non-hospitalized - Activ2 outpatients, so perhaps the 2A did show reduction in viral load, because it was early in the virus stage.

IPIX SHOULD PURSUE MILD TO MODERATE, BOTH HOSPITALIZED AND NON_HOSPITALIZED.